

REFERENCES

- Aly, A.S., Vaughan, A.M., Kappe, S.H., 2009. Malaria parasite development in the mosquito and infection of the mammalian host. *Annu Rev Microbiol* 63, 195-221.
- Baggott, J.E., Morgan, S.L., Ha, T.S., Alarcon, G.S., Koopman, W.J., Krumdieck, C.L., 1993. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. *Clin Exp Rheumatol* 11 Suppl 8, S101-105.
- Balu, B., Adams, J.H., 2007. Advancements in transfection technologies for *Plasmodium*. *Int J Parasitol* 37, 1-10.
- Bates, S.J., Winstanley, P.A., Watkins, W.M., Allouche, A., Bwika, J., Happi, T.C., Kremsner, P.G., Kublin, J.G., Premji, Z., Sibley, C.H., 2004. Rare, highly pyrimethamine-resistant alleles of the *Plasmodium falciparum* dihydrofolate reductase gene from 5 African sites. *The Journal of infectious diseases* 190, 1783-1792.
- Berkhout, B., 1999. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. *J Biomed Sci* 6, 298-305.
- Biles, B.D., Connolly, B.A., 2004. Low-fidelity *Pyrococcus furiosus* DNA polymerase mutants useful in error-prone PCR. *Nucleic Acids Res* 32, e176.
- Bzik, D.J., Li, W.B., Horii, T., Inselburg, J., 1987. Molecular cloning and sequence analysis of the *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase gene. *Proc Natl Acad Sci U S A* 84, 8360-8364.
- Cadwell, R.C., Joyce, G.F., 1992. Randomization of genes by PCR mutagenesis. *PCR Methods Appl* 2, 28-33.
- Carvalho, T.G., Menard, R., 2005. Manipulating the *Plasmodium* genome. *Current issues in molecular biology* 7, 39-55.
- Chanama, M., Chanama, S., Shaw, P.J., Chitnumsub, P., Leartsakulpanich, U., Yuthavong, Y., 2010. Formation of catalytically active cross-species heterodimers of thymidylate synthase from *Plasmodium falciparum* and *Plasmodium vivax*. *Mol Biol Rep* 38, 1029-1037.
- Childs, G.E., Lambros, C., 1986. Analogues of N-benzyloxydihydrotriazines: in vitro antimalarial activity against *Plasmodium falciparum*. *Ann Trop Med Parasitol* 80, 177-181.
- Chunduru, S.K., Cody, V., Luft, J.R., Pangborn, W., Appleman, J.R., Blakley, R.L., 1994. Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions. *The Journal of biological chemistry* 269, 9547-9555.
- Chusacultachai, S., Thiensathit, P., Tarnchompoo, B., Sirawaraporn, W., Yuthavong, Y., 2002. Novel antifolate resistant mutations of *Plasmodium falciparum* dihydrofolate reductase selected in *Escherichia coli*. *Mol Biochem Parasitol* 120, 61-72.

- Chusacultachai, S., Yuthavong, Y., 2004. Random mutagenesis strategies for construction of large and diverse clone libraries of mutated DNA fragments. *Methods Mol Biol* 270, 319-334.
- Cirino, P.C., Mayer, K.M., Umeno, D., 2003. Generating mutant libraries using error-prone PCR. *Methods Mol Biol* 231, 3-9.
- Crabb, B.S., Cooke, B.M., Reeder, J.C., Waller, R.F., Caruana, S.R., Davern, K.M., Wickham, M.E., Brown, G.V., Coppel, R.L., Cowman, A.F., 1997. Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. *Cell* 89, 287-296.
- Crabb, B.S., Cowman, A.F., 1996. Characterization of promoters and stable transfection by homologous and nonhomologous recombination in *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* 93, 7289-7294.
- Cruz, A., Beverley, S.M., 1990. Gene replacement in parasitic protozoa. *Nature* 348, 171-173.
- de Koning-Ward, T.F., Fidock, D.A., Thathy, V., Menard, R., van Spaendonk, R.M., Waters, A.P., Janse, C.J., 2000a. The selectable marker human dihydrofolate reductase enables sequential genetic manipulation of the *Plasmodium berghei* genome. *Mol Biochem Parasitol* 106, 199-212.
- de Koning-Ward, T.F., Janse, C.J., Waters, A.P., 2000b. The development of genetic tools for dissecting the biology of malaria parasites. *Annu Rev Microbiol* 54, 157-185.
- de Koning-Ward, T.F., Thomas, A.W., Waters, A.P., Janse, C.J., 1998. Stable expression of green fluorescent protein in blood and mosquito stages of *Plasmodium berghei*. *Mol Biochem Parasitol* 97, 247-252.
- Dechering, K.J., Kaan, A.M., Mbacham, W., Wirth, D.F., Eling, W., Konings, R.N., Stunnenberg, H.G., 1999. Isolation and functional characterization of two distinct sexual-stage-specific promoters of the human malaria parasite *Plasmodium falciparum*. *Mol Cell Biol* 19, 967-978.
- Dechering, K.J., Thompson, J., Dodemont, H.J., Eling, W., Konings, R.N., 1997. Developmentally regulated expression of pfs16, a marker for sexual differentiation of the human malaria parasite *Plasmodium falciparum*. *Mol Biochem Parasitol* 89, 235-244.
- Dittrich, S., Mitchell, S.L., Blagborough, A.M., Wang, Q., Wang, P., Sims, P.F., Hyde, J.E., 2008. An atypical orthologue of 6-pyruvoyltetrahydropterin synthase can provide the missing link in the folate biosynthesis pathway of malaria parasites. *Molecular microbiology* 67, 609-618.
- Doerig, C., Abdi, A., Bland, N., Eschenlauer, S., Dorin-Semlat, D., Fennell, C., Halbert, J., Holland, Z., Nivez, M.P., Semlat, J.P., Sicard, A., Reininger, L., 2009. Malaria: targeting parasite and host cell kinomes. *Biochim Biophys Acta* 1804, 604-612.
- Donald, R.G., Carter, D., Ullman, B., Roos, D.S., 1996. Insertional tagging, cloning, and expression of the *Toxoplasma gondii* hypoxanthine-xanthine-guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. *J Biol Chem* 271, 14010-14019.

- Donald, R.G., Roos, D.S., 1993. Stable molecular transformation of *Toxoplasma gondii*: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. *Proc Natl Acad Sci U S A* 90, 11703-11707.
- Dower, W.J., Miller, J.F., Ragsdale, C.W., 1988. High efficiency transformation of *E. coli* by high voltage electroporation. *Nucleic Acids Res* 16, 6127-6145.
- Duangrudee, T., 2004. Crystal structure of *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase in complex with trimethoprim. Mahidol University, Graduate Studies.
- Eid, J., Sollner-Webb, B., 1991. Stable integrative transformation of *Trypanosoma brucei* that occurs exclusively by homologous recombination. *Proc Natl Acad Sci U S A* 88, 2118-2121.
- Elion, G.B., Hitchings, G.H., 1950. Antagonist of nucleic acid derivatives. III. The specificity of the purine requirement of *Lactobacillus casei*. *J Biol Chem* 185, 651-655.
- Emond, S., Mondon, P., Pizzut-Serin, S., Douchy, L., Crozet, F., Bouayadi, K., Kharrat, H., Potocki-Veronese, G., Monsan, P., Remaud-Simeon, M., 2008. A novel random mutagenesis approach using human mutagenic DNA polymerases to generate enzyme variant libraries. *Protein Eng Des Sel* 21, 267-274.
- Esposito, R., 1991. [Chemoprophylaxis and chemotherapy of malaria in the 90s]. *G Ital Chemioter* 38, 75-77.
- Ferlan, J.T., Mookherjee, S., Okezie, I.N., Fulgence, L., Sibley, C.H., 2001. Mutagenesis of dihydrofolate reductase from *Plasmodium falciparum*: analysis in *Saccharomyces cerevisiae* of triple mutant alleles resistant to pyrimethamine or WR99210. *Molecular and biochemical parasitology* 113, 139-150.
- Fernandez, A., Tawfik, D.S., Berkhout, B., Sanders, R., Kloczkowski, A., Sen, T., Jernigan, B., 2005. Protein promiscuity: drug resistance and native functions--HIV-1 case. *J Biomol Struct Dyn* 22, 615-624.
- Fidock, D.A., Nomura, T., Wellems, T.E., 1998. Cycloguanil and its parent compound proguanil demonstrate distinct activities against *Plasmodium falciparum* malaria parasites transformed with human dihydrofolate reductase. *Mol Pharmacol* 54, 1140-1147.
- Fidock, D.A., Wellems, T.E., 1997. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. *Proc Natl Acad Sci U S A* 94, 10931-10936.
- Foote, S.J., Galatis, D., Cowman, A.F., 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of *Plasmodium falciparum* involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. *Proc Natl Acad Sci U S A* 87, 3014-3017.
- Franke-Fayard, B., Trueman, H., Ramesar, J., Mendoza, J., van der Keur, M., van der Linden, R., Sinden, R.E., Waters, A.P., Janse, C.J., 2004. A *Plasmodium berghei* reference line that constitutively expresses GFP at a high level throughout the complete life cycle. *Molecular and biochemical parasitology* 137, 23-33.

- Galivan, J., Nimec, Z., Rhee, M., Boschelli, D., Oronsky, A.L., Kerwar, S.S., 1988. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate. *Cancer Res* 48, 2421-2425.
- Giraldo, L.E., Acosta, M.C., Labrada, L.A., Praba, A., Montenegro-James, S., Saravia, N.G., Krogstad, D.J., 1998. Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in *Plasmodium falciparum* from southwest Colombia. *Am J Trop Med Hyg* 59, 124-128.
- Goonewardene, R., Daily, J., Kaslow, D., Sullivan, T.J., Duffy, P., Carter, R., Mendis, K., Wirth, D., 1993. Transfection of the malaria parasite and expression of firefly luciferase. *Proc Natl Acad Sci U S A* 90, 5234-5236.
- Gregson, A., Plowe, C.V., 2005. Mechanisms of resistance of malaria parasites to antifolates. *Pharmacol Rev* 57, 117-145.
- Gresch, O., Engel, F.B., Nesic, D., Tran, T.T., England, H.M., Hickman, E.S., Korner, I., Gan, L., Chen, S., Castro-Obregon, S., Hammermann, R., Wolf, J., Muller-Hartmann, H., Nix, M., Siebenkotten, G., Kraus, G., Lun, K., 2004. New non-viral method for gene transfer into primary cells. *Methods* 33, 151-163.
- Hankins, E.G., Warhurst, D.C., Sibley, C.H., 2001. Novel alleles of the *Plasmodium falciparum* dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. *Molecular and biochemical parasitology* 117, 91-102.
- Hastings, M.D., Bates, S.J., Blackstone, E.A., Monks, S.M., Mutabingwa, T.K., Sibley, C.H., 2002. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of *Plasmodium falciparum* from Tanzania. *Trans R Soc Trop Med Hyg* 96, 674-676.
- Haynes, R.K., Chan, H.W., Ho, W.Y., Ko, C.K., Gerena, L., Kyle, D.E., Peters, W., Robinson, B.L., 2005. Convenient access both to highly antimalaria-active 10-arylaminoartemisinins, and to 10-alkyl ethers including artemether, arteether, and artelinate. *Chembiochem* 6, 659-667.
- Hitchings, G.H., Burchall, J.J., 1965. Inhibition of folate biosynthesis and function as a basis for chemotherapy. *Adv Enzymol Relat Areas Mol Biol* 27, 417-468.
- Hitchings, G.H., Falco, E.A., Elion, G.B., Singer, S., Waring, G.B., Hutchison, D.J., Burchenal, J.H., 1952a. 2, 4-Diaminopyrimidines as antagonists of folic acid and folinic acid. *Arch Biochem Biophys* 40, 479-481.
- Hitchings, G.H., Falco, E.A., Vanderwerff, H., Russell, P.B., Elion, G.B., 1952b. Antagonists of nucleic acid derivatives. VII. 2, 4-Diaminopyrimidines. *J Biol Chem* 199, 43-56.
- Horrocks, P., Kilbey, B.J., 1996. Physical and functional mapping of the transcriptional start sites of *Plasmodium falciparum* proliferating cell nuclear antigen. *Mol Biochem Parasitol* 82, 207-215.
- Horrocks, P., Lanzer, M., 1999. Mutational analysis identifies a five base pair cis-acting sequence essential for GBP130 promoter activity in *Plasmodium falciparum*. *Mol Biochem Parasitol* 99, 77-87.
- Hunt, S.Y., Detering, C., Varani, G., Jacobus, D.P., Schiehsler, G.A., Shieh, H.M., Nevchas, I., Terpinski, J., Sibley, C.H., 2005. Identification of the optimal third generation antifolate against *P. falciparum* and *P. vivax*. *Mol Biochem Parasitol* 144, 198-205.

- Hurly, M.G., 1959. Potentiation of pyrimethamine by sulphadiazine in human malaria. *Trans R Soc Trop Med Hyg* 53, 412-413.
- Hyde, J.E., 1990. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. *Pharmacol Ther* 48, 45-59.
- Hyde, J.E., 2005. Exploring the folate pathway in *Plasmodium falciparum*. *Acta tropica* 94, 191-206.
- Ivanetich, K.M., Santi, D.V., 1990. Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa. *FASEB J* 4, 1591-1597.
- Janse, C.J., Camargo, A., Del Portillo, H.A., Herrera, S., Kumlien, S., Mons, B., Thomas, A., Waters, A.P., 1994. Removal of leucocytes from *Plasmodium vivax*-infected blood. *Ann Trop Med Parasitol* 88, 213-216.
- Janse, C.J., Franke-Fayard, B., Mair, G.R., Ramesar, J., Thiel, C., Engelmann, S., Matuschewski, K., van Gemert, G.J., Sauerwein, R.W., Waters, A.P., 2006a. High efficiency transfection of *Plasmodium berghei* facilitates novel selection procedures. *Mol Biochem Parasitol* 145, 60-70.
- Janse, C.J., Franke-Fayard, B., Waters, A.P., 2006b. Selection by flow-sorting of genetically transformed, GFP-expressing blood stages of the rodent malaria parasite, *Plasmodium berghei*. *Nature protocols* 1, 614-623.
- Janse, C.J., Ramesar, J., Waters, A.P., 2006c. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite *Plasmodium berghei*. *Nat Protoc* 1, 346-356.
- Janse, C.J., Waters, A.P., 1995. *Plasmodium berghei*: the application of cultivation and purification techniques to molecular studies of malaria parasites. *Parasitol Today* 11, 138-143.
- Japrun, D., Leartsakulpanich, U., Chusacultanachai, S., Yuthavong, Y., 2007. Conflicting requirements of *Plasmodium falciparum* dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination. *Antimicrob Agents Chemother* 51, 4356-4360.
- Kain, K.C., Shanks, G.D., Keystone, J.S., 2001. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. *Clin Infect Dis* 33, 226-234.
- Kamen, B., 1997. Folate and antifolate pharmacology. *Semin Oncol* 24, S18-30-S18-39.
- Keuth, U., Sabbagh, M., Thesen, E., 1970. [Therapy of bacterial infections in infants and children. Report of 171 cases treated with trimethoprim-sulfamethoxazol]. *Munch Med Wochenschr* 112, 802-806.
- Knapen, M.F., van der Wildt, B., Sijtsma, E.G., Peters, W.H., Roelofs, H.M., Steegers, E.A., 1999. Glutathione S-transferase Alpha 1-1 and aminotransferases in umbilical cord blood. *Early Hum Dev* 54, 129-135.
- Krungskrai, J., Yuthavong, Y., Webster, H.K., 1989. High-performance liquid chromatographic assay for thymidylate synthase from the human malaria parasite, *Plasmodium falciparum*. *J Chromatogr* 487, 51-59.
- Leclerc, P.G., Panjwani, A., Docherty, R., Berry, M., Pizzey, J., Tonge, D.A., 2005. Effective gene delivery to adult neurons by a modified form of electroporation. *J Neurosci Methods* 142, 137-143.

- Lee, M.G., Van der Ploeg, L.H., 1990. Homologous recombination and stable transfection in the parasitic protozoan *Trypanosoma brucei*. *Science* 250, 1583-1587.
- Lemcke, T., Christensen, I.T., Jorgensen, F.S., 1999. Towards an understanding of drug resistance in malaria: three-dimensional structure of *Plasmodium falciparum* dihydrofolate reductase by homology building. *Bioorg Med Chem* 7, 1003-1011.
- Lobo, C.A., Fujioka, H., Aikawa, M., Kumar, N., 1999. Disruption of the Pfg27 locus by homologous recombination leads to loss of the sexual phenotype in *P. falciparum*. *Mol Cell* 3, 793-798.
- Maasho, K., Marusina, A., Reynolds, N.M., Coligan, J.E., Borrego, F., 2004. Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system. *J Immunol Methods* 284, 133-140.
- Maciel, C., de Oliveira Junior, V.X., Fazio, M.A., Nacif-Pimenta, R., Miranda, A., Pimenta, P.F., Capurro, M.L., 2008. Anti-plasmodium activity of angiotensin II and related synthetic peptides. *PLoS One* 3, e3296.
- Mandel, M., Higa, A., 1970. Calcium-dependent bacteriophage DNA infection. *J Mol Biol* 53, 159-162.
- Martin, D.C., Arnold, J.D., 1968. Treatment of acute falciparum malaria with sulfalene and trimethoprim. *JAMA* 203, 476-480.
- McGregor, I.A., Williams, K., Goodwin, L.G., 1963. Pyrimethamine and Sulphadiazine in Treatment of Malaria. *Br Med J* 2, 728-729.
- McGuire, J.J., 2003. Anticancer antifolates: current status and future directions. *Curr Pharm Des* 9, 2593-2613.
- McKie, J.H., Douglas, K.T., Chan, C., Roser, S.A., Yates, R., Read, M., Hyde, J.E., Dascombe, M.J., Yuthavong, Y., Sirawaraporn, W., 1998. Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. *J Med Chem* 41, 1367-1370.
- Meisner, H., Carter, J.R., Jr., 1977. Regulation of lipolysis in adipose tissue. *Horizons in biochemistry and biophysics* 4, 91-129.
- Michel, R., 1968. [Comparative study of the association of sulfalene and pyrimethamine and of sulfalene alone in mass chemoprophylaxis of malaria]. *Med Trop (Mars)* 28, 488-494.
- Nash, L.A., Peterson, L.N., Nadler, S.P., Levine, D.Z., 1988. Determination of sodium and potassium in nanoliter volumes of biological fluids by furnace atomic absorption spectrometry. *Anal Chem* 60, 2413-2418.
- Neylon, C., 2004. Chemical and biochemical strategies for the randomization of protein encoding DNA sequences: library construction methods for directed evolution. *Nucleic Acids Res* 32, 1448-1459.
- Nunes, A., Thathy, V., Bruderer, T., Sultan, A.A., Nussenzweig, R.S., Menard, R., 1999. Subtle mutagenesis by ends-in recombination in malaria parasites. *Mol Cell Biol* 19, 2895-2902.

- Nzila-Mounda, A., Mberu, E.K., Sibley, C.H., Plowe, C.V., Winstanley, P.A., Watkins, W.M., 1998. Kenyan *Plasmodium falciparum* field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. *Antimicrob Agents Chemother* 42, 164-169.
- Nzila, A., 2006. The past, present and future of antifolates in the treatment of *Plasmodium falciparum* infection. *The Journal of antimicrobial chemotherapy* 57, 1043-1054.
- O'Donnell, R.A., Freitas-Junior, L.H., Preiser, P.R., Williamson, D.H., Duraisingh, M., McElwain, T.F., Scherf, A., Cowman, A.F., Crabb, B.S., 2002. A genetic screen for improved plasmid segregation reveals a role for Rep20 in the interaction of *Plasmodium falciparum* chromosomes. *The EMBO journal* 21, 1231-1239.
- Olliaro, P.L., Yuthavong, Y., 1999. An overview of chemotherapeutic targets for antimalarial drug discovery. *Pharmacol Ther* 81, 91-110.
- Orr-Weaver, T.L., Szostak, J.W., Rothstein, R.J., 1981. Yeast transformation: a model system for the study of recombination. *Proc Natl Acad Sci U S A* 78, 6354-6358.
- Peters, W., 1975. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of *P. berghei* in screening for blood schizontocidal activity. *Ann Trop Med Parasitol* 69, 155-171.
- Peters, W.H., te Morsche, R.H., Roelofs, H.M., Mathus-Vliegen, E.M., Berkhout, M., Nagengast, F.M., 2009. COX-2 polymorphisms in patients with familial adenomatous polyposis. *Oncol Res* 17, 347-351.
- Peterson, D.S., Milhous, W.K., Wellems, T.E., 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in *Plasmodium falciparum* malaria. *Proc Natl Acad Sci U S A* 87, 3018-3022.
- Peterson, D.S., Walliker, D., Wellems, T.E., 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in *falciparum* malaria. *Proc Natl Acad Sci U S A* 85, 9114-9118.
- Prendergast, N.J., Appleman, J.R., Delcamp, T.J., Blakley, R.L., Freisheim, J.H., 1989. Effects of conversion of phenylalanine-31 to leucine on the function of human dihydrofolate reductase. *Biochemistry* 28, 4645-4650.
- Rastelli, G., Sirawaraporn, W., Sompornpisut, P., Vilaivan, T., Kamchonwongpaisan, S., Quarrell, R., Lowe, G., Thebtaranonth, Y., Yuthavong, Y., 2000. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with *Plasmodium falciparum* dihydrofolate reductase: structural basis of antifolate resistance. *Bioorg Med Chem* 8, 1117-1128.
- Rothstein, R., 1991. Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast. *Methods Enzymol* 194, 281-301.
- Scherer, S., Davis, R.W., 1979. Replacement of chromosome segments with altered DNA sequences constructed in vitro. *Proc Natl Acad Sci U S A* 76, 4951-4955.

- Schlitzer, M., 2007. Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. *ChemMedChem* 2, 944-986.
- Shafikhani, S., Siegel, R.A., Ferrari, E., Schellenberger, V., 1997. Generation of large libraries of random mutants in *Bacillus subtilis* by PCR-based plasmid multimerization. *Biotechniques* 23, 304-310.
- Shanks, G.D., Kain, K.C., Keystone, J.S., 2001. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. *Clin Infect Dis* 33, 381-385.
- Sibley, C.H., Hyde, J.E., Sims, P.F., Plowe, C.V., Kublin, J.G., Mberu, E.K., Cowman, A.F., Winstanley, P.A., Watkins, W.M., Nzila, A.M., 2001. Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: what next? *Trends Parasitol* 17, 582-588.
- Singh, M., Ghose, T., Kralovec, J., Blair, A.H., Belitsky, P., 1991. Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor model. *Cancer Immunol Immunother* 32, 331-334.
- Sirawaraporn, W., 1998. Dihydrofolate reductase and antifolate resistance in malaria. *Drug Resist Updat* 1, 397-406.
- Sirawaraporn, W., Sathitkul, T., Sirawaraporn, R., Yuthavong, Y., Santi, D.V., 1997. Antifolate-resistant mutants of *Plasmodium falciparum* dihydrofolate reductase. *Proc Natl Acad Sci U S A* 94, 1124-1129.
- Snewin, V.A., England, S.M., Sims, P.F., Hyde, J.E., 1989. Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. *Gene* 76, 41-52.
- Soskine, M., Tawfik, D.S., 2000. Mutational effects and the evolution of new protein functions. *Nat Rev Genet* 11, 572-582.
- Soskine, M., Tawfik, D.S., 2010. Mutational effects and the evolution of new protein functions. *Nat Rev Genet* 11, 572-582.
- Spee, J.H., de Vos, W.M., Kuipers, O.P., 1993. Efficient random mutagenesis method with adjustable mutation frequency by use of PCR and dITP. *Nucleic Acids Res* 21, 777-778.
- Sultan, A.A., Thathy, V., Frevert, U., Robson, K.J., Crisanti, A., Nussenzweig, V., Nussenzweig, R.S., Menard, R., 1997. TRAP is necessary for gliding motility and infectivity of *Plasmodium* sporozoites. *Cell* 90, 511-522.
- Thathy, V., Menard, R., 2002. Gene targeting in *Plasmodium berghei*. *Methods Mol Med* 72, 317-331.
- Tomas, A.M., van der Wel, A.M., Thomas, A.W., Janse, C.J., Waters, A.P., 1998. Transfection systems for animal models of malaria. *Parasitol Today* 14, 245-249.
- Toyoda, T., Brobey, R.K., Sano, G., Horii, T., Tomioka, N., Itai, A., 1997. Lead discovery of inhibitors of the dihydrofolate reductase domain of *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase. *Biochem Biophys Res Commun* 235, 515-519.
- Urdaneta, L., Plowe, C., Goldman, I., Lal, A.A., 1999. Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of *Plasmodium falciparum* isolates from Venezuela. *Am J Trop Med Hyg* 61, 457-462.

- van der Wel, A.M., Tomas, A.M., Kocken, C.H., Malhotra, P., Janse, C.J., Waters, A.P., Thomas, A.W., 1997. Transfection of the primate malaria parasite *Plasmodium knowlesi* using entirely heterologous constructs. *J Exp Med* 185, 1499-1503.
- van Dijk, M.R., Waters, A.P., Janse, C.J., 1995. Stable transfection of malaria parasite blood stages. *Science* 268, 1358-1362.
- Vasconcelos, K.F., Plowe, C.V., Fontes, C.J., Kyle, D., Wirth, D.F., Pereira da Silva, L.H., Zalis, M.G., 2000. Mutations in *Plasmodium falciparum* dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. *Memorias do Instituto Oswaldo Cruz* 95, 721-728.
- Volpato, J.P., Pelletier, J.N., 2009. Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison. *Drug Resist Updat* 12, 28-41.
- Walliker, D., Hunt, P., Babiker, H., 2005. Fitness of drug-resistant malaria parasites. *Acta tropica* 94, 251-259.
- Warhurst, D.C., 1998. Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance. *Drug discovery today* 3, 538-546.
- Watkins, W.M., Brandling-Bennett, A.D., Oloo, A.J., Howells, R.E., Gilles, H.M., Koech, D.K., 1987. Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. *Lancet* 1, 125-128.
- Wernsdorfer, W.H., 1990. Chemoprophylaxis of malaria: underlying principles and their realization. *Med Trop (Mars)* 50, 119-124.
- WHO, 2010. World malaria report 2010. WHO press.
- Winstanley, P.A., 2000. Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. *Parasitol Today* 16, 146-153.
- Wu, Y., Sifri, C.D., Lei, H.H., Su, X.Z., Wellems, T.E., 1995. Transfection of *Plasmodium falciparum* within human red blood cells. *Proc Natl Acad Sci U S A* 92, 973-977.
- Yuthavong, Y., 2002. Basis for antifolate action and resistance in malaria. *Microbes Infect* 4, 175-182.
- Yuvaniyama, J., Chitnumsub, P., Kamchonwongpaisan, S., Vanichtanankul, J., Sirawaraporn, W., Taylor, P., Walkinshaw, M.D., Yuthavong, Y., 2003. Insights into antifolate resistance from malarial DHFR-TS structures. *Nat Struct Biol* 10, 357-365.
- Zaccolo, M., Williams, D.M., Brown, D.M., Gherardi, E., 1996. An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. *J Mol Biol* 255, 589-603.